Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending ...

Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO.O), opens new tab jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the ...

The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a ...

Agios expects Aqvesme to be available in late January 2026 following full REMS implementation. H.C. Wainwright updated its model to reflect a first-quarter 2026 commercial launch and increased the ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...

Tennis star Aryna Sabalenka and businessman Georgios Frangulis are a couple with a nine-year age gap. Sabalenka, a top player, is younger than Frangulis, a Brazilian entrepreneur. Their relationship, ...

CAMBRIDGE - The U.S. Food and Drug Administration (FDA) has not issued a decision on Agios Pharmaceuticals’ (NASDAQ:AGIO) supplemental New Drug Application (sNDA) for mitapivat by its expected ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

As Aryna Sabalenka continues her ascent through the top ranks of women's tennis, her boyfriend Georgios Frangulis has become a steady presence in her player's box and a central figure in her personal ...

Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...